Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DCPS | Q96C86 | 6/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | F2R | P25116 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6630735 | 0.82 | DCPS (0.43) | DCPSHTTNPC1ALDH1A1RAB9A | |
| SCHEMBL6630767 | 0.76 | F2R (0.46) | DCPSHTTF2R | |
| SCHEMBL6630676 | 0.73 | HTT (0.35) | DCPSHTTF2R | |
| SCHEMBL6795053 | 0.73 | F2R (0.48) | DCPSHTTALDH1A1ADORA2AF2R | |
| SCHEMBL6630874 | 0.64 | TRPM5 (0.35) | HTTALDH1A1 | |
| SCHEMBL6630460 | 0.64 | CYP1A2 (0.38) | ALDH1A1ADORA2AF2R | |
| SCHEMBL24166434 | 0.62 | F2R (0.49) | F2R | |
| SCHEMBL21121770 | 0.56 | SMN1; SMN2 (0.48) | HTTALDH1A1SMN1; SMN2ADORA2A | |
| Bromide SCHEMBL21121865 | 0.56 | SMN1; SMN2 (0.47) | HTTALDH1A1SMN1; SMN2ADORA2A | |
| SCHEMBL10197977 | 0.55 | HTR2C (0.68) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1370560-B1 | AMINOMETHYL-PYRROLOQUINAZOLINE COMPOUNDS AS THROMBIN RECEPTOR ANTAGONISTS | ORTHO MCNEIL PHARM INC (US) | 2004-11-10 | — | — | EP | claimed |
| US-20020160963-A1 | Aminomethyl-pyrroloquinazoline compounds as thrombin receptor antagonists | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2002-10-31 | — | — | US | claimed |
| EP-1370560-B1 | AMINOMETHYL-PYRROLOQUINAZOLINE COMPOUNDS AS THROMBIN RECEPTOR ANTAGONISTS | ORTHO MCNEIL PHARM INC (US) | 2004-11-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020160963-A1 | Aminomethyl-pyrroloquinazoline compounds as thrombin receptor antagonists | F2R, F2RL1, F2RL3 | DCPS 1532/4885HTT 2936/4885NPC1 4273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.